
Phoenix Biotechnology: Pioneering cancer treatment research and therapeutic agent development.
Phoenix Biotechnology, founded in Texas, is dedicated to the research and development of therapeutic agents and treatment regimens for cancer, antiviral, and neuro-degenerative diseases. The company specializes in creating safe and effective natural products, particularly focusing on the therapeutic potential of Nerium oleander. Their core mission is to address diseases with unmet medical needs and significant economic impacts on livestock health, aiming to make their treatments widely accessible at low costs.
Notable figures associated with Phoenix Biotechnology include leading researchers and scientists in the field of oncology and virology. The company has garnered attention from key investors interested in innovative cancer treatments. Among its achievements, Phoenix Biotechnology has developed promising data that support the efficacy and safety of their natural products, positioning them as a significant player in the biotech industry. Their impact is marked by a commitment to advancing medical science and improving patient outcomes through natural therapeutic solutions.

Nerium Biotechnology
nbiresearch.com

Phoenix Life Sciences International
phoenixlife.co

Nerx Biosciences

BioNumerik Pharmaceuticals

Puma Biotechnology

Phoenix PharmaLabs

PNP Therapeutics

Phigenix
phigenix.com

Tigris Pharmaceuticals
tigrispharma.com

Oncolix

NanoPharmaceuticals

Biotheryx
biotheryx.com

PDX Pharmaceuticals
pdxpharm.com

NantBio

Phoenix S&T
phoenix-st.com
Companies similar to Phoenix Biotechnology include Nerium Biotechnology, Phoenix Life Sciences International, Nerx Biosciences and BioNumerik Pharmaceuticals.
Phoenix Biotechnology was founded in 2003.
Phoenix Biotechnology's headquarters is located in San Antonio, TX, US.
Phoenix Biotechnology's most recent funding round was for $5M (USD) in August 2020.
As of Aug 12, 2020, Phoenix Biotechnology has raised a total of $10.9M (USD).
Phoenix Biotechnology has 6 employees as of Feb 5, 2024.